PagerDuty

Recent news

• Rating change
  A Quick Look at Today's Ratings for PagerDuty(PD.US), With a Forecast Between $9.5 to $15
  Market Newswire · 2026/8/29
• Precision Drilling: Authorized to Acquire Up to 1.2M Common Shares for Cancellation PD.T
  Dow Jones · 2026/9/17
• Company notice
  QD PD B2803: NOTICE OF LISTING ON THE STOCK EXCHANGE OF HONG KONG LIMITED - QINGDAO PINGDU HOLDINGS GROUP CO., LTD. - U.S.$84,000,000 6.9 per cent. Social Bonds due 2028
  HKEX · 2025/3/11
• Rating change
  Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $13
  Market Newswire · 2026/8/20
• Rating change
  RBC Capital Maintains PagerDuty(PD.US) With Hold Rating, Raises Target Price to $12
  Market Newswire · 2026/8/14
• AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug...
  Benzinga · 2026/9/29
• Rating change
  BofA Securities Maintains PagerDuty(PD.US) With Sell Rating, Raises Target Price to $8
  Market Newswire · 2026/7/22
• Merck & Co.'s PD-1 inhibitor pembrolizumab injection (subcutaneous) approved in China
  Latest · 2026/9/29
• Rating change
  Morgan Stanley Downgrades PagerDuty(PD.US) to Sell Rating, Maintains Target Price $9
  Market Newswire · 2026/7/22
• Rating change
  Monness Maintains PagerDuty(PD.US) With Hold Rating
  Market Newswire · 2026/8/24
• Rating change
  TD Cowen Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $13.5
  Market Newswire · 2026/8/26
• Company notice
  Immutep Ltd: Fourth U.S. Patent Secured for Efti and PD-1 Combination
  ASX · 2026/7/14
• Wellist Biologics-B (09887.HK): The pivotal Phase IIB registration study of Wellistimab (Opatisumab, a PD-L1/4-1BB bispecific antibody) as monotherapy for advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC) has been selected as a Late-Breaking Abstract (LBA), and three studies have been chosen for preferred oral presentation.
  Gelonghui Finance · 2026/9/21
• Company notice
  CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY) RECEIVES U.S. FDA IND CLEARANCE FOR PHASE II CLINICAL TRIAL
  HKEX · 2026/2/16
• Company notice
  QD PD B2803: PUBLICATION OF THE OFFERING CIRCULAR - QINGDAO PINGDU HOLDINGS GROUP CO., LTD. - U.S.$84,000,000 6.9 per cent. Social Bonds due 2028
  HKEX · 2025/3/12
• Rating change
  Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $11
  Market Newswire · 2026/7/9
• Rating change
  Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Maintains Target Price $11
  Market Newswire · 2026/7/14
• Company notice
  LEADS BIOLABS-B: VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
  HKEX · 2026/1/14
• WeLide Bio-B (09887): The pivotal Phase IIb registration study of WeLixin (opatilimab, a PD-L1/4-1BB bispecific antibody) as monotherapy for advanced EP-NEC was selected as a Late-Breaking Abstract (LBA), and three additional studies were selected for preferred oral presentation.
  Zhitong Finance · 2026/9/21
• Rating change
  Morgan Stanley Maintains PagerDuty(PD.US) With Sell Rating, Maintains Target Price $10
  Market Newswire · 2026/9/18

Headlines are aggregated automatically and are not independently verified or edited by our team.